or Try an Advanced Search...

    Technical Analysis for REPL - Replimune Group, Inc.

    Grade Last Price % Change Price Change
    D 16.50 -0.60% -0.10
    REPL closed down 0.6 percent on Thursday, September 28, 2023, on 1.47 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical REPL trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Outside Day Range Expansion -0.60%
    Wide Bands Range Expansion -0.60%
    Oversold Stochastic Weakness -0.60%
    Wide Bands Range Expansion 3.38%
    Down 3 Days in a Row Weakness 3.38%
    Oversold Stochastic Weakness 3.38%
    Wide Bands Range Expansion 2.17%
    Older End-of-Day Signals for REPL ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Down 3% about 12 hours ago
    60 Minute Opening Range Breakdown about 12 hours ago
    Down 2 % about 12 hours ago
    10 DMA Resistance about 12 hours ago
    1.5x Volume Pace about 12 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    REPL Chart by TradingView
    Basic chart:

    Profile

    Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1

    Is REPL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 19 Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Sep 19 Replimune Group appoints CFO
    Sep 19 Replimune Announces Appointment of Emily Hill as Chief Financial Officer
    Sep 14 Insider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group Inc
    Aug 14 Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch
    Aug 3 Replimmune down 8% on skin cancer cancer candidate data delay
    Aug 3 Replimune Group GAAP EPS of -$0.75
    Aug 3 Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
    Jul 31 Replimune, Incyte to collaborate on squamous cell carcinoma combo
    Jul 31 Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
    See more REPL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 29.5229
    52 Week Low 15.51
    Average Volume 536,148
    200-Day Moving Average 21.41
    50-Day Moving Average 19.32
    20-Day Moving Average 18.23
    10-Day Moving Average 16.91
    Average True Range 0.86
    RSI (14) 32.43
    ADX 38.09
    +DI 8.74
    -DI 28.46
    Chandelier Exit (Long, 3 ATRs) 18.73
    Chandelier Exit (Short, 3 ATRs) 18.22
    Upper Bollinger Bands 21.14
    Lower Bollinger Band 15.32
    Percent B (%b) 0.2
    BandWidth 31.93
    MACD Line -0.99
    MACD Signal Line -0.80
    MACD Histogram -0.1836
    Fundamentals Value
    Market Cap 758.38 Million
    Num Shares 46 Million
    EPS -1.01
    Price-to-Earnings (P/E) Ratio -16.27
    Price-to-Sales 0.00
    Price-to-Book 7.94
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 17.88
    Resistance 3 (R3) 17.86 17.38 17.65
    Resistance 2 (R2) 17.38 17.03 17.39 17.57
    Resistance 1 (R1) 16.94 16.81 16.70 16.96 17.50
    Pivot Point 16.46 16.46 16.34 16.47 16.46
    Support 1 (S1) 16.02 16.11 15.78 16.04 15.50
    Support 2 (S2) 15.54 15.89 15.55 15.43
    Support 3 (S3) 15.10 15.54 15.35
    Support 4 (S4) 15.12